[go: up one dir, main page]

PE20181924A1 - Inhibidores de la arginasa y sus aplicaciones terapeuticas - Google Patents

Inhibidores de la arginasa y sus aplicaciones terapeuticas

Info

Publication number
PE20181924A1
PE20181924A1 PE2018002300A PE2018002300A PE20181924A1 PE 20181924 A1 PE20181924 A1 PE 20181924A1 PE 2018002300 A PE2018002300 A PE 2018002300A PE 2018002300 A PE2018002300 A PE 2018002300A PE 20181924 A1 PE20181924 A1 PE 20181924A1
Authority
PE
Peru
Prior art keywords
boronoethyl
amino
linear
arginase
branched
Prior art date
Application number
PE2018002300A
Other languages
English (en)
Inventor
Roman Blaszczyk
Julita Nowicka
Bartlomiej Borek
Joanna Brzezinska
Anna Gzik
Marek Dziegielewski
Adam Golebiowski
Karol Jedrzejczak
Krzysztof Matyszewski
Jacek Olczak
Original Assignee
Oncoarendi Therapeutics Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoarendi Therapeutics Sa filed Critical Oncoarendi Therapeutics Sa
Publication of PE20181924A1 publication Critical patent/PE20181924A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a un compuesto de formula i en donde l es CO2H, -C(O)O(alquilo(C1-C6), entre otros; R1 puede ser H, alquilo (C1-C6) lineal o ramificado, entre otros X, Y, Z pueden ser -C(R´)(R´´)-, -C(R´´)2, entre otros; Z y L forman opcionalmente un anillo de lactona fusionado que tiene de 4 a 7 atomos miembros del anillo; m, n, p son enteros entre 0 y 2; R2 Y R3 tomados junto con el atomo de boro y oxigeno forman un anillo de 4, 5, 6 o 7 miembros; v puede ser -C(R´)(R´´)-, -NR´, entre otros; W puede ser -C(R´)(R´´´)-; D puede ser alquileno (C1-C5) lineal o ramificado, alquenileno(C2-C8) lineal o ramificado. Son compuestos preferidos acido 1-amino-3-(2-boronoetil)ciclopentano-1-carboxilico, acido 1-amino-3-(2-boronoetil)-2-metilciclopentano-1-carboxilico, clorhidrato del acido 1-amino-3-(boronoetil)ciclopentano-1-carboxilico. Dichos compuestos terapeuticos de moleculas pequenas son potentes inhibidores de la actividad de la Arginasa 1 y Arginasa 2. Tambien se refiere a una composicion farmaceutica y un metodo de tratamiento que son utiles en el tratamiento del cancer.
PE2018002300A 2016-05-04 2017-05-02 Inhibidores de la arginasa y sus aplicaciones terapeuticas PE20181924A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662331550P 2016-05-04 2016-05-04
PL417066A PL417066A1 (pl) 2016-05-04 2016-05-04 Inhibitory arginazy oraz ich zastosowania terapeutyczne
US201762444669P 2017-01-10 2017-01-10

Publications (1)

Publication Number Publication Date
PE20181924A1 true PE20181924A1 (es) 2018-12-11

Family

ID=60190450

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018002300A PE20181924A1 (es) 2016-05-04 2017-05-02 Inhibidores de la arginasa y sus aplicaciones terapeuticas

Country Status (24)

Country Link
US (3) US10391077B2 (es)
EP (1) EP3452485B1 (es)
JP (1) JP6971477B2 (es)
KR (1) KR102374788B1 (es)
CN (1) CN109415387B (es)
AU (1) AU2017259887B2 (es)
BR (1) BR112018072545B1 (es)
CA (1) CA3022482C (es)
CL (1) CL2018003132A1 (es)
CO (1) CO2018013077A2 (es)
DK (1) DK3452485T3 (es)
ES (1) ES2834065T3 (es)
HR (1) HRP20201821T1 (es)
HU (1) HUE052468T2 (es)
IL (1) IL262387B (es)
LT (1) LT3452485T (es)
MX (1) MX378806B (es)
PE (1) PE20181924A1 (es)
PH (1) PH12018501976A1 (es)
PL (2) PL417066A1 (es)
SA (1) SA518400356B1 (es)
SG (1) SG11201807974QA (es)
SI (1) SI3452485T1 (es)
WO (1) WO2017191130A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
NZ742742A (en) 2015-10-30 2023-04-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
WO2017155879A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
TWI818902B (zh) 2016-12-22 2023-10-21 美商卡利泰拉生物科技公司 用於抑制精胺酸酶活性的組合物及方法
US11420984B2 (en) 2018-02-17 2022-08-23 Astrazeneca Ab Arginase inhibitors and methods of use thereof
CR20200445A (es) * 2018-03-05 2021-04-27 Arcus Biosciences Inc Inhibidores de la arginasa
EP3765006A4 (en) * 2018-03-13 2022-02-23 Merck Sharp & Dohme Corp. ARGINASE INHIBITORS AND METHODS OF USE
AU2019246728A1 (en) 2018-03-29 2020-08-27 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
US11274111B2 (en) 2018-06-20 2022-03-15 Merck Sharp & Dohme Corp. Arginase inhibitors and methods of use
CN113382998A (zh) 2018-11-16 2021-09-10 艾库斯生物科学有限公司 Arg1和/或arg2的抑制剂
US12240867B2 (en) 2018-12-18 2025-03-04 Merck Sharp & Dohme Llc Arginase inhibitors and methods of use
KR20220100904A (ko) 2019-11-12 2022-07-18 남미 테라퓨틱스, 인크. 암의 치료에 유용한 ido 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
EP4087583A4 (en) * 2020-01-07 2024-01-24 Merck Sharp & Dohme LLC Arginase inhibitors and methods of use
TW202228720A (zh) * 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
WO2024209358A1 (en) 2023-04-06 2024-10-10 Molecure S.A. Process for the production of (1r,2s,5r)-1-amino-5-[2-(dihydroxyboranyl)ethyl]-2-[(dimethylamino)methyl]cyclohexane-1-carboxylic acid

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ241954A (en) 1991-03-15 1994-01-26 Amgen Inc Compositions of g-csf for pulmonary administration.
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
AU9797998A (en) 1997-10-10 1999-05-03 Trustees Of The University Of Pennsylvania, The Compositions and methods for inhibiting arginase activity
EP1604977A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals CIS pyrrolidinyl derivatives and their uses
EP1604978A1 (en) 2004-06-02 2005-12-14 Faust Pharmaceuticals Trans pyrrolidinyl derivatives and their pharmaceutical uses
EP2083812B1 (en) 2006-11-21 2017-04-05 Rijksuniversiteit Groningen Use of arginase inhibitors in the treatment of asthma and allergic rhinitis
US20100189644A1 (en) 2009-01-26 2010-07-29 The Trustees Of The University Of Pennsylvania Arginase inhibitors and methods of use
WO2011133653A1 (en) 2010-04-22 2011-10-27 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
WO2012025155A1 (en) 2010-08-26 2012-03-01 Novartis Ag Hydroxamate-based inhibitors of deacetylases
PL2632927T3 (pl) 2010-10-26 2016-09-30 Boroniany jako inhibitory arginazy
WO2012091757A1 (en) 2010-12-31 2012-07-05 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
CN104244932B (zh) 2011-10-19 2017-02-22 马尔斯公司 精氨酸酶抑制剂和其治疗应用
WO2013158262A1 (en) * 2012-04-18 2013-10-24 Mars, Incorporated Ring constrained analogs as arginase inhibitors
EP2872515B1 (en) 2012-07-13 2016-06-08 Janssen Sciences Ireland UC Macrocyclic purines for the treatment of viral infections
PL410665A1 (pl) 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
EP3313410A4 (en) 2015-06-23 2019-01-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
NZ742742A (en) 2015-10-30 2023-04-28 Calithera Biosciences Inc Compositions and methods for inhibiting arginase activity
PL417066A1 (pl) * 2016-05-04 2017-11-06 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
CA3125797A1 (en) 2018-01-28 2019-08-01 Universite De Geneve Arginase suppression for cancer treatment

Also Published As

Publication number Publication date
EP3452485A2 (en) 2019-03-13
WO2017191130A2 (en) 2017-11-09
CO2018013077A2 (es) 2019-04-30
JP6971477B2 (ja) 2021-11-24
CA3022482C (en) 2024-06-11
US20170319536A1 (en) 2017-11-09
MX378806B (es) 2025-03-11
CN109415387A (zh) 2019-03-01
PH12018501976A1 (en) 2019-07-01
MX2018013387A (es) 2019-02-28
HUE052468T2 (hu) 2021-04-28
US10391077B2 (en) 2019-08-27
PL3452485T3 (pl) 2021-04-19
CL2018003132A1 (es) 2019-02-22
WO2017191130A4 (en) 2018-03-01
JP2019518726A (ja) 2019-07-04
HRP20201821T1 (hr) 2021-04-16
IL262387A (en) 2018-12-31
US20190365701A1 (en) 2019-12-05
IL262387B (en) 2021-10-31
US20210260019A1 (en) 2021-08-26
AU2017259887A1 (en) 2018-09-27
KR102374788B1 (ko) 2022-03-15
SA518400356B1 (ar) 2022-01-19
LT3452485T (lt) 2020-12-28
SG11201807974QA (en) 2018-10-30
US12053451B2 (en) 2024-08-06
BR112018072545A2 (pt) 2019-06-25
ES2834065T3 (es) 2021-06-16
AU2017259887B2 (en) 2022-03-17
CA3022482A1 (en) 2017-11-09
CN109415387B (zh) 2021-08-27
WO2017191130A3 (en) 2017-12-14
BR112018072545B1 (pt) 2022-08-23
PL417066A1 (pl) 2017-11-06
EP3452485B1 (en) 2020-09-09
DK3452485T3 (da) 2020-11-09
KR20190015250A (ko) 2019-02-13
NZ746211A (en) 2024-12-20
SI3452485T1 (sl) 2021-01-29
US10912755B2 (en) 2021-02-09

Similar Documents

Publication Publication Date Title
PE20181924A1 (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
AR120700A1 (es) Inhibidores de kras g12c
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
AR086254A1 (es) Derivados de imidazol utiles para el tratamiento de artritis
AR107694A1 (es) Heteroarilos inhibidores de pad4
PE20191540A1 (es) DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA
PE20191020A1 (es) Compuestos quimicos
EA201890450A1 (ru) Циклические динуклеотидные соединения в качестве агонистов sting
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
ES2631611T3 (es) Amidas de piperidina de Pirano-Espirociclico como moduladores de canales iónicos
PE20210478A1 (es) Compuestos heteroaromaticos como inhibidores de vanina
PE20180040A1 (es) Derivados de 2-(feniloxi o feniltio)pirimidina como herbicidas
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos
PE20150724A1 (es) Inhibidores de dgat1 de eter ciclico de cabeza de puente
AR077080A1 (es) Compuestos de 2,3-dihidro-1h-indeno
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
PE20171335A1 (es) Inhibidores de gingipaina de lisina
CR20150419A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
CL2023001367A1 (es) Inhibidores de btk
PE20191142A1 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
MX2018011721A (es) Compuesto de griseofulvina.
PE20200932A1 (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2019004978A2 (es) Compuestos terapéuticos y métodos para utilizarlos